Linagliptin Viatris (Linagliptin)

Linagliptin works by selectively inhibiting the dipeptidyl peptidase‑4 enzyme, which normally degrades incretin hormones such as GLP‑1 and GIP. By preserving these hormones, linagliptin enhances glucose‑dependent insulin secretion and reduces glucagon release, leading to lower blood glucose levels after meals.

The specific dose of Linagliptin Viatris is determined by the prescribing healthcare professional based on the individual’s clinical condition, renal and hepatic function, and concomitant medications. Patients should follow the prescriber’s instructions and not alter the dose without medical advice.

Safety of linagliptin in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Linagliptin belongs to the DPP‑4 inhibitor class, which differs from sulfonylureas, metformin, and SGLT2 inhibitors in its mechanism of preserving incretin hormones. Compared with sulfonylureas, it carries a lower risk of hypoglycaemia when used alone, and unlike metformin, it does not require dose adjustment in renal impairment.

Linagliptin Viatris tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect from moisture and light. Keep the product out of reach of children and avoid exposure to excessive heat or humidity.

Linagliptin Viatris is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with water. Patients should follow the dosing schedule prescribed by their healthcare professional.

Serious risks include pancreatitis, severe allergic reactions such as anaphylaxis, and rare cases of bullous pemphigoid. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash, swelling, or any signs of an allergic reaction.

Linagliptin Viatris should not be used by individuals with a known hypersensitivity to linagliptin or any component of the formulation. Caution is advised in patients with a history of pancreatitis, severe hepatic impairment, or those who are pregnant or breastfeeding unless deemed necessary by a physician.